866-997-4948(US-Canada Toll Free)

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016

Published By :

Global Markets Direct

Published Date : May 2016

Category :

Cancer

No. of Pages : 504 Pages

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016

Summary

Global Markets Directs, Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H1 2016, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma)
- The report reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bile Duct Cancer (Cholangiocarcinoma) therapeutics and enlists all their major and minor projects
- The report assesses Bile Duct Cancer (Cholangiocarcinoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma)


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 6
Bile Duct Cancer (Cholangiocarcinoma) Overview 7
Therapeutics Development 8
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 10
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 14
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 15
Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 18
Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 23
Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 24
Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 79
Drug Profiles 93
Bile Duct Cancer (Cholangiocarcinoma) - Recent Pipeline Updates 288
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 480
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 482
Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 483
Appendix 494

List of Tables
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2016 17
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Development by Companies, H1 2016 (Contd..1) 20
Number of Products under Development by Companies, H1 2016 (Contd..2) 21
Number of Products under Development by Companies, H1 2016 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Late Stage Development, H1 2016 24
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Development, H1 2016 26
Products under Development by Companies, H1 2016 27
Products under Development by Companies, H1 2016 (Contd..1) 28
Products under Development by Companies, H1 2016 (Contd..2) 29
Products under Development by Companies, H1 2016 (Contd..3) 30
Products under Development by Companies, H1 2016 (Contd..4) 31
Products under Investigation by Universities/Institutes, H1 2016 32
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H1 2016 33
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016 34
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals, Inc., H1 2016 35
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 36
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule, Inc., H1 2016 37
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc., H1 2016 38
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 39
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016 40
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H1 2016 41
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H1 2016 42
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corporation, H1 2016 43
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 44
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical, Inc., H1 2016 45
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H1 2016 46
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corporation, H1 2016 47
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H1 2016 48
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corporation, H1 2016 49
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 50
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia Healthcare Corp., H1 2016 51
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 52
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems, Inc., H1 2016 53
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co., Ltd., H1 2016 54
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H1 2016 55
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis, Inc., H1 2016 56
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 57
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics, Inc., H1 2016 58
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc., H1 2016 59
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H1 2016 60
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co., Ltd., H1 2016 61
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology, Inc., H1 2016 62
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co., Ltd., H1 2016 63
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune, LLC, H1 2016 64
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co., Inc., H1 2016 65
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 66
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co., Ltd., H1 2016 67
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys, Inc., H1 2016 68
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H1 2016 69
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Limited, H1 2016 70
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science, Inc., H1 2016 71
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 72
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 73
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H1 2016 74
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc., H1 2016 75
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Plexxikon Inc., H1 2016 76
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H1 2016 77
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology, Inc., H1 2016 78
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd., H1 2016 79
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H1 2016 80
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences, Inc., H1 2016 81
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 82
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 83
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 84
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H1 2016 85
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 86
Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics, Inc., H1 2016 87
Assessment by Monotherapy Products, H1 2016 88
Assessment by Combination Products, H1 2016 89
Number of Products by Stage and Target, H1 2016 91
Number of Products by Stage and Mechanism of Action, H1 2016 95
Number of Products by Stage and Route of Administration, H1 2016 99
Number of Products by Stage and Molecule Type, H1 2016 101
Bile Duct Cancer (Cholangiocarcinoma) Therapeutics - Recent Pipeline Updates, H1 2016 297
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H1 2016 489
Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H1 2016 490
Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H1 2016 491

List of Figures
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H1 2016 17
Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H1 2016 18
Number of Products under Development by Companies, H1 2016 19
Number of Products under Investigation by Universities/Institutes, H1 2016 23
Comparative Analysis by Clinical Stage Development, H1 2016 25
Comparative Analysis by Early Stage Products, H1 2016 26
Assessment by Monotherapy Products, H1 2016 88
Number of Products by Top 10 Targets, H1 2016 90
Number of Products by Stage and Top 10 Targets, H1 2016 90
Number of Products by Top 10 Mechanism of Actions, H1 2016 94
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 94
Number of Products by Routes of Administration, H1 2016 98
Number of Products by Stage and Routes of Administration, H1 2016 98
Number of Products by Molecule Types, H1 2016 100
Number of Products by Stage and Molecule Types, H1 2016 100

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *